Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 23Prostatic Neoplasms 18Wilms Tumor 12Kidney Neoplasms 11Neoplasm Metastasis 8Carcinoma, Renal Cell 8Urethral Neoplasms 6Sarcoma 6Colorectal Neoplasms 4Breast Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Neoplasms 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Ureteral Neoplasms 2Sarcoma, Synovial 2Sarcoma, Endometrial Stromal 2Pheochromocytoma 2Pancreatic Neoplasms 2Neurofibrosarcoma 2Neuroblastoma 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Multiple Myeloma 2Melanoma 2Malignant mesenchymal tumor 2Liposarcoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2

Interventions

durvalumab 1Vinblastine 1Methotrexate 1Gemcitabine 1Doxorubicin 1Cystectomy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bladder Adenocarcinoma × Doxorubicin × Genitourinary × Clear all
NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Stanford University

Phase 2 Terminated
7 enrolled 9 charts
GenitourinarySarcoma

Bladder Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡